in this issue
People & Business :: Green Issues
Blog: A Bumpy, Slow Transformation to Biomaterials?
8:32 AM MDT | October 18, 2010 | Alex Scott
Although it is widely accepted that one day cheap oil will run out, even in a world of seemingly generous government funding some biomaterial technology providers are struggling to deliver the solutions while maintaining profitability. Verenium (Cambridge, MA), a biotech firm, could be one such company: Laurence Alexander, an analyst with investment bank Jefferies and Company (New York), in a recent report, downgraded forecast 2010 earnings per share for Verenium from $0.35 to a loss of $2.2. Alexander doesn’t opt for a positive stance in 2011...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee